tbuckley/cabot-search huggingface dataset:
Liver resection after hepatic arterial infusion (HAI) plus systemic oxaliplatin (Oxal) combinations in pretreated patients with extensive unresectable colorectal liver metastases
Authors: G. D. Leonard, Y. Fong, W. Jarnagin, R. Harris, L. Schwartz, M. D'Angelica, P. Paty, R. Dematteo, L. Blumgart, N. Kemeny
Journal: Journal of Clinical Oncology (2004)

3542 Background: Metastatic colorectal cancer has a 5-year survival < 5% but increases to 30% in patients (pts) who undergo complete resection. Neoadjuvant systemic (SYS) chemotherapy may increase the proportion of patients suitable for resection, but this is unlikely to occur after first line chemotherapy failure, given the 10 - 15% response rates of second line SYS Oxal (Rothenberg et al, J Clin Oncol 2003:21;2059, Tournigand et al, Proc Am Soc Clin Oncol 2001;20:abstr 494). HAI plus SYS Oxal may be more effective in this regard, especially in previously treated patients. Methods: Forty-four patients with liver only metastatic colorectal cancer were deemed unresectable by experienced hepatobiliary surgeons. They were treated on either of two phase I trials consisting of HAI (floxuridine and dexamethasone) plus either SYS Oxal with irinotecan (CPT-11) or SYS Oxal with fluorouracil and leucovorin. Responding pts proceeded to surgery if deemed resectable. Results: The overall response rate using HAI plus SYS Oxal was 82% in the 44 unresectable patients despite 70% of pts having progressed on prior SYS CPT-11. Sixteen pts (36%) had minimal residual disease post HAI plus SYS Oxal, 9 pts (20%) have already had complete gross resection of liver metastases while the other 7 are being considered for resection. To illustrate the extent of disease in the 44 pts in this study, the characteristics of these pts are compared with the largest study in the literature that used SYS neoadjuvant chemotherapy alone in mostly chemotherapy naïve pts (Table 1). Conclusions: HAI plus SYS Oxal combinations achieved a high response rate which allowed resection in at least 20% (to potentially 36%) of pts, who have already progressed on the latest generation of SYS chemotherapy and who have extensive liver metastases. No significant financial relationships to disclose.
Diffuse MRI Marrow Pattern Correlates with Increased Angiogenesis, Advanced Disease Features and Poor Prognosis in Newly-Diagnosed Patients with Multiple Myeloma Treated with Novel Agents.
Authors: Lia A. Moulopoulos, Evangelos Terpos, Dimitrios Christoulas, Efstathios Kastritis, Dimitra Anagnostou, Andreas Koureas, Maria Roussou, Maria Gavriatopoulou, Magdalini Migkou, Marina Iakovaki, Maria Gkotzamanidou, Vasilios Skiadas, Anna Tasidou, Meletios A. Dimopoulos
Journal: Blood (2009)
GENETIC RISK, ADHERENCE TO A HEALTHY LIFESTYLE, AND RISK OF CORONARY ARTERY DISEASE
Authors: Amit V. Khera, Connor A. Emdin, Isabel Drake, Pradeep Natarajan, Alexander Bick, Nancy Cook, Daniel Chasman, Usman Baber, Roxana Mehran, Daniel Rader, Valentin Fuster, Eric Boerwinkle, Melander Olle, Marju Orho-Melander, Paul Ridker, Sekar Kathiresan
Journal: Journal of the American College of Cardiology (2017)
COMPARISON OF TIMING OF NON-CULPRIT LESION PERCUTANEOUS CORONARY INTERVENTION IN MYOCARDIAL INFARCTION PATIENTS
Authors: Hyung Oh Kim, Jong-Shin Woo, Jung Myung Lee, Jin-Bae Kim, Soo-Joong Kim, Woo-Shik Kim, Kim Kwon Sam, Weon Kim, Hyemoon Chung, Jae Min Kim
Journal: Journal of the American College of Cardiology (2017)
CONTRAST-INDUCED NEPHROPATHY FOLLOWING PERIPHERAL ANGIOGRAPHY WITH CARBON DIOXIDE VERSUS IODINATED CONTRAST MEDIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF CURRENT LITERATURE
Authors: Saad Sultan Ghumman, Jonathan Weinerman, Aazib Khan, Mubeen Cheema, Dan Levin, Rajeev Suri, Marlene Garcia, Anand Prasad
Journal: Journal of the American College of Cardiology (2017)
Reply: The ATS/JRS Guidelines on Lymphangioleiomyomatosis: Filling in the Gaps
Authors: Francis X. McCormack, Nishant Gupta, Geraldine R. Finlay, Lisa R. Young, Simon R. Johnson, Vincent Cottin, Kevin C. Wilson, Joel Moss
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

only one of the studies (6).Thus, the proposed threshold serum level is based on the results obtained by a single laboratory.Although the fundamentals of LAM have been extensively discussed, with special regard to therapeutic issues, other more general aspects concerning the practical management of the disease should be considered, such as use of bronchodilators, pulmonary rehabilitation, and indications for lung transplant.Pregnancy and air travel limitation are two further matters of great importance for the general pulmonologist and should be discussed and dealt with separately.
A randomized phase II study of ipilimumab induction in patients with melanoma brain metastases receiving stereotactic radiosurgery.
Authors: Ann W. Silk, Yue Cao, Diana Gomez-Hassan, Bruce G. Redman, James Hayman, Jason Heth, Christopher D. Lao
Journal: Journal of Clinical Oncology (2015)

TPS9079 Background: Despite recent advances in the treatment of metastatic melanoma, survival remains poor in patients who develop brain metastases. Radiation therapy continues to be the backbone of treatment of brain metastases. Stereotactic radiosurgery (SRS) is a type of external radiation therapy that uses multiple beams to deliver a large dose of radiation to a tumor in a single session. The use of immunotherapy may complement radiation therapy because the latter damages the blood brain barrier (BBB), alters the tumor microenvironment, and increases immunogenicity of tumors. Ipilimumab, an immune checkpoint inhibitor, improves survival in patients with metastatic melanoma. The time to best response after ipilimumab is often several months, emphasizing the need for early initiation of treatment. Ipilimumab has a 16% response rate in patients with brain metastases who are neurologically asymptomatic. Previous studies have suggested that treatment with SRS and ipilimumab was associated with a 16-month prolongation in overall survival as compared to SRS alone. The optimal combination schedule to induce effective antitumor immunity is unknown. We hypothesize that “induction” with ipilimumab prior to SRS will improve control of the irradiated metastases. The trial will explore the use of dynamic contrast-enhanced (DCE) MRI as a potential imaging biomarker for predicting tumor response. DCE MRI is a functional imaging technique that can quantitatively map the spatial distribution of physiologic vascular parameters in the brain, such as regional cerebral blood volume and gadolinium-DTPA transfer constant, which is a measure of “leakiness” across the BBB. Methods: This is a randomized phase II “pick the winner” selection study. Forty subjects with 1-4 asymptomatic brain metastases will be randomized to one of two sequences of therapy: either ipilimumab (3 mg/kg IV every 3 weeks x 2 doses) bracketing SRS (Induction arm), or SRS followed by ipilimumab (3 mg/kg IV every 3 weeks x 4 doses; No Induction arm). The primary endpoint is the rate of control of the irradiated metastases at 6 months assessed by MRI. DCE-MRI and various immune parameters will be explored as potential biomarkers. Clinical trial information: NCT02097732.
A NOVEL SCORE TO PREDICT OUTCOME IN PATIENTS SUPPORTED BY VENO-ARTERIAL EXTRACORPOREAL MEMBRANE OXYGENATION
Authors: Sakir Akin, Kadir Caliskan, Osama Soliman, L.S.D. Jewbali, Corstiaan den Uil, Atila Kara, Alina Constantinescu, Robert J. van Thiel, Ron van Domburg, Jan Bakker, Dinis dos Reis Miranda
Journal: Journal of the American College of Cardiology (2017)
LIPID LEVELS AND VASCULAR FUNCTION IN YOUNG INDIVIDUALS, HETEROZYGOUS OR HOMOZYGOUS FOR AN APOB C.1058G&gt;A VARIANT
Authors: Devyani Chowdhury, Christine Pascua, Millie Young, Michael Horst, Michael A. McCulloch, Samuel Gidding, Erik Puffenberger, Kevin Strauss, Katie Williams
Journal: Journal of the American College of Cardiology (2017)
NUISANCE BLEEDING IN ANTICOAGULATED PATIENTS WITH ATRIAL FIBRILLATION: INSIGHTS FROM THE OUTCOMES REGISTRY FOR BETTER INFORMED TREATMENT OF ATRIAL FIBRILLATION (ORBIT-AF)
Authors: Emily Claire O'Brien, DaJuanicia Simon, Laine Thomas, Daniel Singer, Peter Kowey, Gerald Naccarelli, Gregg Fonarow, James A. Reiffel, Jack Ansell, Alan S. Go, Paul Chan, Michael Ezekowitz, Bernard Gersh, Larry Allen, James Freeman, Kenneth Mahaffey, Jonathan Piccini, Eric Peterson, Elaine Hylek
Journal: Journal of the American College of Cardiology (2017)
OPTICAL COHERENCE TOMOGRAPHY OF CULPRIT LESIONS IN PATIENTS WITH PRIOR CEREBROVASCULAR EVENTS COMPARED TO CONTROLS
Authors: Ines Sherifi, Yuliya Vengrenyuk, Sunil Agarwal, Jonathan Halperin, Jacobo Pena, Usman Baber, Pedro Moreno, Samin Sharma, Jagat Narula, Annapoorna Kini
Journal: Journal of the American College of Cardiology (2017)
Abstract #5461: Active component isolated from human urine extract (CDA-2) has activities of eliminating cancer stem-like cells and inhibition of epithelial mesenchymal transition
Authors: Chih-Jung Yao, Chi-Tai Yeh, Chuan-Feng Yeh, Chih-Kai Chang, Chi-Han Li, Jiann-Long Yan, Shuang-En Chuang, Gi-Ming Lai
Journal: Cancer Research (2009)

AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

Recently, the concept of \#8220;cancer stem cell\#8221; may renew the notion of designing cancer therapy. The progression and relapse of tumor may be initiated by the remaining cancer stem cells that escaped from conventional cancer treatments such as chemotherapy and radiation. The research for therapeutics targeting this small population of cancer stem cells is badly needed. By UV laser equipped flow cytometer and cell-permeable DNA binding dye Hoechst 33342, a distinct side population (SP) cells expressing high-level of ATP-binding cassette transporter protein ABCG2/Bcrp1, could be identified and sorted. These SP cells possess characteristics of stem cells such as self renewal and expression of stemness genes. Using this stem-like SP cells as a model, our previous studies had found that a human urine extract CDA-2 could eliminate SP cells in Huh7 hepatoma cells and down-regulate the expression of stemness genes such as CD133 , SMO , Oct-4 and \#946; -catenin . In addition, CDA-2 was also found to inhibit the EGF-induced epithelial-mesenchymal transition (EMT) in A549 lung cancer cells. Therefore, it is interesting to find any active component from CDA-2 that plays the key role. After solvent extraction and HPLC separation, a peak in the HPLC profile named as P23.2 was found to possess the activities of SP cell elimination and EMT inhibition. After 48 h incubation with Huh7 hepatoma cells, the percentage of SP cells was decreased from 1.26% to 0.17% by CDA-2 at dose of 4 mg/ml, in contrast, P23.2 reduced the SP cells from 1.69% to 0.18% at dose of 25 \#956;g/ml, indicating the P23.2 was about 160 times more potent than CDA-2. Moreover, the P23.2 also exerted inhibitory effects on the EGF-induced EMT in A549 lung cancer cells as that did by CDA-2. Not only the mesenchymal-like morphologic changes but also the decreased epithelial marker E-cadherin and the elevated Snail (E-cadherin repressor) m-RNA expressions were almost completely reversed by 50 \#956;g/ml of P23.2. These results indicate the existence of active component in human urine, which may have the potential for cancer control. Further identification and subsequent modification of chemical structure of P23.2 as novel therapeutic is warranted.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 5461.
CORRELATION BETWEEN ECHOCARDIOGRAPHIC PULMONARY ARTERY PRESSURE ESTIMATES AND RIGHT HEART CATHETERIZATION MEASUREMENTS IN PATIENTS UNDERGOING LIVER TRANSPLANT EVALUATION: A SINGLE CENTER STUDY
Authors: Fuad Habash, Pooja Gurram, Ahmed Almomani, Andres Duarte-Rojo, Abdul Hakeem, Srikanth Vallurupalli, Sabha Bhatti
Journal: Journal of the American College of Cardiology (2017)
COMPARISON OF THE USE OF CARDIOVASCULAR RISK EQUATIONS BY HEALTH TECHNOLOGY ASSESSMENT BODIES AND CLINICAL GUIDELINES
Authors: Sandra Milev, Marissa Blieden, Hyosung Jung, Meredith Hoog, Yi Qian, Christine Edwards, Guillermo Villa, Lucie Kutikova, Alexandra Ward, Anne Beaubrun
Journal: Journal of the American College of Cardiology (2017)
TPF versus PF as induction therapy in unresectable head and neck cancer: A pharmacoeconomic analysis
Authors: N. L. Liberato, L. Licitra, J. Bogaerts, G. Danese, M. Marchetti, S. Quaglini, C. Rognoni, S. Rubrichi, J. B. Vermorken
Journal: Journal of Clinical Oncology (2009)

6075 Background: Adding docetaxel to induction therapy with PF has been shown to improve overall survival of patients with head and neck cancer. On the basis of the raw data from the EORTC trial 24971/TAX 323 a pharmacoeconomic analysis has been performed. A National Healthcare System perspective and a 5-years temporal horizon have been adopted. Methods: A decision-analytic approach has been adopted, and a Markov model has been used to represent patient's weekly transitions among different health states, related to treatment (chemotherapy, radiotherapy, surgeries, palliative care) and disease status (complete/partial/no response, progression, recurrence). Constant or time-variant costs and quality of life adjustment factors have been assigned to each health state, together with transition probabilities to other states. A 3% discount factor has been used for costs sustained after the first year. The model allowed calculating expected life years (LYs), quality adjusted life years (QALYs) and costs. From these figures, incremental cost/effectiveness (ICER) and cost/utility (ICUR) ratios have been calculated. Robustness of results obtained with baseline values has been tested with probabilistic multivariate sensitivity analysis. Results: In the base case analysis, treatment with TPF yields an expectancy of 2.38 LYs and 1.53 QALYs at a cost of Euro (E) 23,018, which for PF were 1.93 LYs, 1.11 QALYs, and E 19,567, respectively. ICER and ICUR were E 7,669/LY and E 8,217/QALY, respectively. Sensitivity analyses were performed varying transition probabilities of 10%, costs of 30% and utility scores of 20% of their basal values. The analyses showed that 86% and 84% of the results lie below the threshold of E 50,000/LY and E 50,000/QALY, respectively. Conclusions: In our analysis TPF induction chemotherapy proved to be cost-effective with respect to PF, having an ICER and ICUR comparable to other widely accepted healthcare interventions. [Table: see text]
LEFT BUNDE BRANCH BLOCK IS INCOMPLETE IN THE MAJORITY OF PATIENTS WITH HEART FAILURE DUE TO SYSTOLIC LEFT VENTRICLE DYSFUNCTION: A SIMPLE INTRAPROCEDURAL DEMONSTRATION
Authors: Dan-Andrei Radu, Corneliu Nicolae Iorgulescu, Stefan Nicolae Bogdan, Elena Ene, Alexandrina Nastasa, Georgiana Gratiela Malaescu, Radu-Gabriel Vatasescu
Journal: Journal of the American College of Cardiology (2017)
SAFETY AND FEASIBILITY OF MELODY TRANSCATHETER PULMONARY VALVE REPLACEMENT IN THE NATIVE RIGHT VENTRICULAR OUTFLOW TRACT: A MULTICENTER STUDY
Authors: Mary Hunt Martin, Jeffery Meadows, Bryan Goldstein, Lisa Bergersen, Athar Qureshi, Shabana Shahanavaz, Jamil Aboulhosn, Darren Berman, Lynn Peng, Matthew Gillespie, Aimee Armstrong, Cindy Weng, Robert Gray
Journal: Journal of the American College of Cardiology (2017)
A phase I/II study of Enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intraperitoneally (IP): Dose finding and proof of concept in platinum-resistant epithelial ovarian cancer.
Authors: Iain A. McNeish, Agnieszka Michael, Chris Twelves, Rosalind Glasspool, Mazhar A. Ajaz, Rosemary Morrison, Ourania Xeniou, Richard Brown, Kerry Fisher, Christine Blanc
Journal: Journal of Clinical Oncology (2015)

TPS5611 Background: Enadenotucirev (EnAd) is a tumor selective Ad11/Ad3 group B adenovirus that has demonstrated preclinical activity in a model of platinum-resistant ovarian cancer. Synergy has also been reported between oncolytic adenoviruses and microtubule manipulating drugs (Ingemarsdotter, Oncogene, 2010, 29(45)). EnAd is suited to IP delivery as it avoids its elimination by the liver and retains it in the peritoneal cavity, where ovarian cancer metastases are principally located. This study aims to establish the maximum-tolerated dose (MTD) of EnAd delivered IP, both as a monotherapy (Phase [Ph.] Ia) and combined with paclitaxel (Ph. Ib) and provide early proof of concept data (Ph. II). Methods: Ph. I follows a standard 3+3 dose escalation scheme and Ph. II is a single arm. Patients (pts) with platinum-resistant ovarian cancer receive EnAd as 3 separate weekly IP doses followed by 1 week rest (one cycle) in Ph.Ia and EnAd IP on d1, 8 and 15 (±1 d) and weekly paclitaxel (80 mg/m2) IV on d9, 16 and 23 (±1 d) of each 28-day cycle. The starting dose for EnAd in Ph. Ia is 1 x 1012 vp. The MTD determined in Ph. Ib is to be tested in 20-23 pts in Phase II. Primary endpoints include determination of MTD for Ph.I (alone and in combination) and progression-free survival (PFS) using RECIST v1.1 for Ph. II. Secondary endpoints include safety and tolerability, blood kinetics, IP distribution, clearance and replication, shedding, blood and IP immune response to EnAd, blood cytokine response as well as response rate, duration of response, clinical benefit rate and PFS using immune-related response criteria (irRC) and GCIG CA-125 criteria. Exploratory endpoints include assessment of IP cytological changes (inflammatory cell infiltrates) in response to EnAd, and EnAd replication in cancer tissues in selected patients. To date, 3 pts have been treated in Ph. Ia and recruitment is ongoing. Clinical trial information: EUDRACT 2013-001276-38. Clinical trial information: NCT02028117.
Chronic Myeloid Leukemia (CML) Cells Express Tumor Associated Antigens Eliciting Specific CD8+ T Cell Responses Despite of Deficient Expression of Costimulatory Molecules.
Authors: Jochen Greiner, Li Li, Krzysztof Giannopoulos, Christian Brunner, Konstanze Döhner, Hartmut Döhner, Michael Schmitt
Journal: Blood (2005)
THE ASSOCIATION BETWEEN WAIST-HIP RATIO WITH LONG-TERM CARDIOVASCULAR EVENTS IN PATIENTS WITH CORONARY ARTERY DISEASE: A POPULATION-BASED HISTORICAL COHORT STUDY
Authors: Jose Medina, John Batsis, Marta Supervia, Virend Somers, Randal Thomas, Sarah Jenkins, Francisco Lopez-Jimenez
Journal: Journal of the American College of Cardiology (2017)
The individuality of tumor-stroma interaction in non-small cell lung cancer: Insights from functional and molecular analyses
Authors: S. Gottschling, R. Kuner, M. Granzow, E. Chang Xu, T. Muley, H. Hoffmann, H. Dienemann, V. Eckstein, A. D. Ho, M. Thomas, M. Meister
Journal: Journal of Clinical Oncology (2009)

11115 Background: Tumor-stroma interaction plays a significant role for malignant growth. Results from prostate and breast cancer rodent models show cancerogenic properties of tumor-associated and genetically altered stromal cells (SC) when combined with initiated or normal epithelium (Olumi et al., Cancer Res 1999, Kuperwasser et al., PNAS 2004). However, data on the mechanisms and sequels of tumor-stroma interaction in lung cancer are scanty. Methods: Here, we analyzed the functional and molecular sequels of cross-talk between the non-small cell lung cancer (NSCLC) cell lines A549, H23, and H1703 and primary stromal cells (SC) derived from matched normal lung tissue and tumors of newly diagnosed NSCLC patients. Tumor cells were kept in a non-contact co-culture system with SC and analyzed for alterations in proliferation, colony formation, migration, adhesion, invasion, chemosensitivity and gene expression by Affymetrix HG U133 Plus 2.0 arrays. Results: Exposure to SC altered cellular functions and gene expression profiles related to tumor growth, metastasis and response to therapy. Each cell line showed individual alterations that were hierarchically governed by the (1) type of tumor cell, (2) the SC donor and his histology (3) and the local origin of the SC (normal lung tissue vs. tumor-associated). Conclusions: This in vitro model demonstrates an individual pattern of tumor-stroma interaction in NSCLC that is determined by both, the properties of the tumor cells and those of the stromal environment. Thus, biomarker programs in NSCLC should also consider the stromal compartment. No significant financial relationships to disclose.
ASSOCIATION OF ENDOTHELIAL DYSFUNCTION AND ARTERIAL WALL ELASTIC PROPERTIES WITH SYSTEMIC INFLAMMATION IN PATIENTS WITH PSEUDOEXFOLIATIVE GLAUCOMA
Authors: Evangelos Oikonomou, Evgenia Bourouki, Georgia Siasou, Gerasimos Siasos, Marilita Moschos, Nikolaos Gouliopoulos, Theodore Paraskevopoulos, Georgia Vogiatzi, Sotirios Tsalamandris, George-Angelo Papamikroulis, Alexis Antonopoulos, Dimitris Tousoulis
Journal: Journal of the American College of Cardiology (2017)
Abstract P234: S-nitrosylation of Cyclophilin D Attenuates Mitochondrial Permeability Transition Pore Opening: A Critical Role for Cysteine 203 Residue
Authors: Tiffany T Nguyen, Mark V Stevens, Mark J Kohr, Charles Steenbergen, Michael N Sack, Elizabeth Murphy
Journal: Circulation Research (2011)

S-nitrosylation (SNO), a reversible, redox-dependent post-translational modification, has emerged as an important mechanism for dynamic regulation of many proteins. Our previous studies have shown that protein S-nitrosylation (SNO) plays a protective role in myocardial ischemia/reperfusion (IR) injury. The primary mediator of cell death in I/R injury is activation of the mitochondrial permeability transition pore (mPTP). Using a proteomic approach, we have previously found that cyclophilin D (CypD), a critical mPTP regulator, can be SNO on cysteine 203 (C203). To investigate whether SNO of CypD might attenuate mPTP activation, we mutated cysteine 203 of CypD, to a serine residue (C203S) and determined its effects on mPTP opening by assessing H 2 O 2 -induced mPTP opening using the calcein AM-cobalt chloride quenching method. Treatment of CypD -/- mouse embryonic fibroblasts (MEFs) with H 2 O 2 resulted loss in an ≈50 % loss of mPTP opening as compared to WT MEFs (n=5, p&lt;0.05), consistent with the protective role of CypD in mPTP activation. Addition of a nitric oxide donor, GSNO, to CypD -/- MEFs did not further reduce mPTP opening; however, WT MEFs treated GSNO attenuated mPTP opening by half. To elucidate the role of SNO of C203 on CypD, we infected CypD -/- MEFs with a C203S-CypD vector. C203S-CypD re-constituted MEFs were also resistant to mPTP opening in the presence or absence of GSNO. This suggests that C203 is required for mPTP activation. To determine whether in vivo expression of C203S-CypD would alter mPTP opening, we generated adenovirus vectors encoding WT CypD or mutated C203S-CypD and injected these viral particles into CypD -/- mice via tail-vein. Mitochondria isolated from livers of CypD -/- mice or mice expressing C203S-CypD were resistant to Ca 2+ -induced swelling as compared to WT CypD reconstituted mice. In summary, our results indicate that C203 of CypD is required for mPTP opening and for the first time shows that SNO of C203 on CypD acts to attenuate mPTP activation.